8 active
/
28 total (since 2015)
5
Phase 1 Active
11 total
6
Phase 2 Active
12 total
1
Phase 3 Active
5 total
0
Phase 4 Active
6 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Spur Therapeutics 2 1 0
Prevail Therapeutics 2 0 0
Genzyme, a Sanofi Company 1 3 0
Lingyi Biotech Co., Ltd. 1 0 0
Takeda 0 3 0
NCT07223944 NOT YET RECRUITING
A Gaucher Disease Gene Therapy Trial With FLT201
Spur Therapeutics n=45
NCT05529992 COMPLETED
A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease
Takeda n=20
NCT05815004 WITHDRAWN
An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3
AVROBIO
NCT02536755 COMPLETED
Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies
Genzyme, a Sanofi Company n=31
Data: ClinicalTrials.gov